semaglutide for kidney disease Semaglutide, Chronic Disease, and Diabetes Ozempic is first GLP-1 drug

The catalog includes peptide-blends targeting tissue regeneration and extracellular matrix remodeling, metabolic receptor signaling, and modulation of the growth hormone axis

This is conceptually analogous to the mechanism proposed for other bioregulatory peptides, where short sequences derived from tissue-specific proteins serve as epigenetic modulators that restore gene expression patterns toward younger cellular states

Roche has made a significant move by acquiring Carmot Therapeutics for $2.7 billion, following promising Phase I results for its own GLP-1/GIP receptor agonist

Follow the AAOS on Facebook, X, LinkedIn, and Instagram